News

AddToAny

Google+ Facebook Twitter Twitter

Screening to improve mAb-based drugs

By screening potential monoclonal antibody (mAb)-based drugs solely on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.

This finding could enable researchers to overcome a major hurdle to drug development by identifying promising mAb-based therapies, which must be administered via injection, but often lack the properties necessary to succeed as solutions.

“Therapeutic antibodies that neutralise pathogens are a promising way to treat infectious disease,” said Jonathan Kingsbury, study author. “Selection of well-behaved antibodies with molecular properties that enable streamlined manufacturing, scale-up, and subcutaneous delivery is key for rapid development, particularly during a pandemic response.”

The paper says mAb solution behaviour can be predicted with 90% accuracy based on its diffusion interaction parameter.  

bit.ly/2BOGUKj


Picture Credit | Science Photo Library

Related Articles

One-to-one: COVID response controvery

We hear from Professor Sunetra Gupta – the theoretical epidemiologist who believes in herd immunity and doesn’t believe in the lockdown.

"Three times risk for frontline healthcare workers"

Frontline healthcare workers with adequate personal protective equipment (PPE) have a three-fold increased risk of a positive SARS-CoV-2 test, compared with the public.

Immune responses to COVID-19

Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a new study.

Top